These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Seventh Conference on Retroviruses and Opportunistic Infections. Merrick S; Gulick R; Boyle B AIDS Read; 2000 Mar; 10(3):135-9. PubMed ID: 10758009 [No Abstract] [Full Text] [Related]
3. When to switch and what to switch to: strategic use of antiretroviral therapy. Gulick R AIDS Read; 2000 Mar; 10(3):156-61; discussion 171-4. PubMed ID: 10758015 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of combination antiretroviral therapy. Collier AC Adv Exp Med Biol; 1996; 394():355-72. PubMed ID: 8815701 [TBL] [Abstract][Full Text] [Related]
5. [The role of stavudine in antiretroviral therapy]. Molina JM Presse Med; 1998 Oct; 27(33):1708-9. PubMed ID: 9834791 [No Abstract] [Full Text] [Related]
6. Quick reference guide to antiretrovirals. Schütz M Eur J Med Res; 2001 May; 6(5):219-27. PubMed ID: 11410404 [TBL] [Abstract][Full Text] [Related]
7. New wave antiretrovirals. Smart T GMHC Treat Issues; 1996 Sep; 10(9):1-3. PubMed ID: 11363838 [TBL] [Abstract][Full Text] [Related]
8. Different origin of adipogenic stem cells influences the response to antiretroviral drugs. Gibellini L; De Biasi S; Nasi M; Carnevale G; Pisciotta A; Bianchini E; Bartolomeo R; Polo M; De Pol A; Pinti M; Cossarizza A Exp Cell Res; 2015 Oct; 337(2):160-9. PubMed ID: 26238601 [TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781 [TBL] [Abstract][Full Text] [Related]
11. Viral resistance and the selection of antiretroviral combinations. Larder BA J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S28-33. PubMed ID: 8595505 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of drug resistance in human immunodeficiency virus. Richman DD Clin Infect Dis; 1995 Oct; 21 Suppl 2():S166-9. PubMed ID: 8845446 [TBL] [Abstract][Full Text] [Related]
13. Structural mechanisms of HIV drug resistance. Erickson JW; Burt SK Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401 [TBL] [Abstract][Full Text] [Related]
14. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection]. Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135 [No Abstract] [Full Text] [Related]
15. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations. Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885 [No Abstract] [Full Text] [Related]
16. [Drugs active against retroviruses]. Brun-Vézinet F; Descamps D Rev Prat; 1997 Mar; 47(6):631-8. PubMed ID: 9183937 [TBL] [Abstract][Full Text] [Related]
18. Strategies of antiretroviral therapy in adults. Itani S; Bartlett JA Urol Clin North Am; 1999 Nov; 26(4):809-20, ix-x. PubMed ID: 10584621 [TBL] [Abstract][Full Text] [Related]
19. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. Miller LG; Hays RD AIDS Read; 2000 Mar; 10(3):177-85. PubMed ID: 10758022 [TBL] [Abstract][Full Text] [Related]